% 0期刊文章%珍妮弗·康% Christa史伟莎%一个约翰·柯克帕特里克%詹姆斯·赫恩登II % %莱斯利·托马斯·埃里克·Lipp %玛格丽特·约翰逊%大卫阿什利%一个蒂娜事务Annick德斯贾丁斯% %亨利·弗里德曼%凯瑟琳·彼得斯% T原发性脑瘤承认神经重症监护室:单个机构观察研究(p1.6 - 009) % D J神经病学2019% % P p1.6 - 009 V % 92% N % X 15补充目的:我们试图确定人口,承认和放电特性已知的原发性脑瘤患者(pbt)承认我们的神经重症监护病房(ICU)。首页背景:因为缺乏数据描述结果的PBT病人承认存在一个ICU在美国。icu是不愿意承认这些患者由于推定,他们将做不好。设计/方法:这是一个单一机构成人患者的回顾性分析pbt承认一个ICU 7/1/13 - 4/12/18杜克大学医院。患者识别从杜克大学的neurocritical保健和脑瘤数据库。病人的人口统计,肿瘤特点、入院诊断、处置和生存数据收集从数据库和医疗记录审核。进行描述性分析。存活时间确定的日期进入ICU死亡日期。结果:247名患者遇到被确定;然而,147年被排除在外由于住院时间≤2天(主要为选择性切除病人),导致100病人遇到被包括在分析中。总共有94名患者由100年的遭遇。主要组织学诊断为胶质母细胞瘤(四年级)(n = 62, 62%)。 The mean age was 34 yrs (range 19–78). 35 unique diagnoses for admission were identified. The most common admission indications were for clinical trial related catheter infusions (n=33, 33%) and status epilepticus (n=11, 11%). Among the 67 encounters that were not clinical trial related, the discharge disposition of patients was: 11 expired, 8 discharged to hospice, 2 to long-term care, 20 to rehabilitation facility, and 26 home. Median survival time for all patients was 370 days (95% CI: 246–511).Conclusions: This is the first descriptive analysis of patients in the United States with PBTs admitted to an ICU. The majority of patients had a favorable discharge disposition.Disclosure: Dr. Kang has nothing to disclose. Dr. Swisher has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai and UCB. Dr. Kirkpatrick has nothing to disclose. Dr. Herndon II has nothing to disclose. Dr. Lipp has nothing to disclose. Dr. Thomas has nothing to disclose. Dr. Johnson has nothing to disclose. Dr. Ashley has nothing to disclose. Dr. DesJardins has received compensation for serving on the Board of Directors of Istari Oncology. Dr. DesJardins has received research support from Symphogen, Orbus Therapeutics, and Triphase Accelerator Corporation. Dr. Randazzo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novocure. Dr. Friedman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech - consultant and advisory board / Istari - Chief Medical Officer and patent. Dr. Friedman has received compensation for serving on the Board of Directors of Genentech - consultant and advisory board / Istari - Chief Medical Officer and patent. Dr. Peters has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Agios, Eisai, Monteris, and Novocure. Dr. Peters has received research support from Abbvie, Agios, Biomimetix, Eisai, Monteris, Novocure, BMS-Research Protocols and Clinical Trials. %U